Point Biopharma announces publication of preclinical data on PNT2004 program

POINT Biopharma Global announced the publication of preclinical data from their pan-cancer, fibroblast activation protein-alpha-targeted program, PNT2004, at the 2023 Annual Meeting of the Society of Nuclear Medicine & Molecular Imaging, taking place June 24-27, 2023, in Chicago, IL. PNT6555, the lead candidate in the PNT2004 program, led to complete and durable tumor regression and improved survival in HEK-mFAP tumor-bearing mice when chelated to any one of the three radioisotopes studied: lutetium-177, actinium-225, and terbium-161. Additionally, 177Lu-PNT6555 in combination with anti-PD-1 checkpoint blockade was assessed in the aggressive, immunocompetent CT26-mFAP mouse model and demonstrated a significant survival benefit compared to either treatment alone. “By continuing to develop expertise in more isotopes, POINT is better positioned to create optimized next-generation radioligands, which match a ligand’s properties with the most appropriate isotope,” said Joe McCann, Ph.D., Chief Executive Officer of POINT Biopharma. “The expertise to discover and develop new radioligands and advance them into clinical trials has been built into POINT. We look to fill our toolbox of isotopes as full as we can, evaluate them in discovery and development, and aim to bring forward candidates we believe could generate compelling patient benefit.”